Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Becherer, A; Mitterbauer, M; Jaeger, U; Kalhs, P; Greinix, HT; Karanikas, G; Pötzi, C; Raderer, M; Dudczak, R; Kletter, K.
Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Leukemia. 2002; 16(2):260-267
Doi: 10.1038/sj.leu.2402342
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Greinix Hildegard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- We have determined the predictive value of [18F]2-fluoro-2-deoxy-glucose (FDG-PET) in patients with Hodgkin's disease (HD) and aggressive non-Hodgkin's lymphoma (NHL) scheduled for high-dose therapy with stem cell transplantation (HDT/SCT). Inclusion criteria were the presence of an FDG-PET scan after chemotherapy (ChT) within 8 weeks prior to HDT/SCT and available follow-up data. Sixteen patients (10 NHL and six HD) were observed during a follow-up period of 4 to 28 months (median 13 months). Before SCT, five patients had a negative PET, three were weakly positive, two moderately positive, and six strongly positive. None of the five patients with a negative PET before HDT/SCT relapsed and two of three patients with a weakly positive scan are still in remission after HDT/SCT. Of eight patients with a moderate or high positive PET before HDT/SCT, seven relapsed and one died of early HDT/SCT related complications (P< 0.01). Three of eight relapsing patients died of lymphoma 5 to 10 months after SCT and in one additional patient not responding to HDT/SCT, the main cause of death was chronic toxicity 4 months after transplantation. After 12 months, in PET-negative patients the overall and relapse-free survival was 100%, in PET-positive patients 55% and 18%, respectively. In NHL, two patients with negative PET, but with an age-adjusted international prognostic index (AaIPI) of 2 and one with AaIPI = 1 are still in remission. In the seven PET-positive subjects, one patient with AaIPI = 0, three with AaIPI = 1, and two with AaIPI = 2 relapsed. We conclude that FDG-PET is accurate in the prediction of relapse prior to HDT/SCT in patients with lymphoma. It provides additional information when compared with the AaIPI.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Carmustine - administration & dosage
- Combined Modality Therapy -
- Cyclophosphamide - administration & dosage
- Cytarabine - administration & dosage
- Disease-Free Survival -
- Etoposide - administration & dosage
- Female -
- Fluorodeoxyglucose F18 - diagnostic use Fluorodeoxyglucose F18 - pharmacokinetics
- Follow-Up Studies -
- Hematopoietic Stem Cell Transplantation - mortality
- Hodgkin Disease - diagnosis Hodgkin Disease - mortality Hodgkin Disease - radionuclide imaging Hodgkin Disease - therapy
- Humans -
- Lymphoma - drug therapy Lymphoma - mortality Lymphoma - radionuclide imaging Lymphoma - therapy
- Lymphoma, Non-Hodgkin - diagnosis Lymphoma, Non-Hodgkin - mortality Lymphoma, Non-Hodgkin - radionuclide imaging Lymphoma, Non-Hodgkin - therapy
- Male -
- Melphalan - administration & dosage
- Middle Aged -
- Neoplasm Recurrence, Local -
- Podophyllotoxin - administration & dosage
- Prognosis -
- Radiopharmaceuticals - diagnostic use Radiopharmaceuticals - pharmacokinetics
- Survival Analysis -
- Survival Rate -
- Tomography, Emission-Computed -
- Transplantation Conditioning - mortality
- Treatment Outcome -
- Whole-Body Irradiation -
- Find related publications in this database (Keywords)
- lymphoma
- positron emission tomography
- stem cell transplantation
- prognosis